SCHEMBL7343145

SCHEMBL7343145

Cc1csc(NC(=O)c2ccc3cc(C(=N)N)ccc3c2)n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.68
NPC1 O15118 7/20 0.59
RAB9A P51151 7/20 0.59
HPGD P15428 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
GCK P35557 6/20 0.58
GRM5 P41594 1/20 0.58
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
ALDH1A1 P00352 2/20 0.57
LMNA P02545 1/20 0.57
NFKB1 P19838 1/20 0.57
NFKB2 Q00653 1/20 0.57
RELA Q04206 1/20 0.57
GAA P10253 1/20 0.56
PLAU P00749 3/20 0.56
F2 P00734 2/20 0.54
PLG P00747 2/20 0.54
KLKB1 P03952 2/20 0.54
PRSS1 P07477 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7343154 0.80 MAPT (0.60) MAPTNPC1RAB9AHPGDSMN1; SMN2
SCHEMBL7335284 0.78 RAB9A (0.74) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL14137442 0.76 MAPT (0.66) MAPTNPC1RAB9AHPGDSMN1; SMN2
SCHEMBL8560618 0.76 GCK (0.79) MAPTNPC1RAB9AHPGDSMN1; SMN2
SCHEMBL25016228 0.76 MAPT (0.46) MAPTNPC1RAB9AHPGDSMN1; SMN2
SCHEMBL7340320 0.75 GRM5 (0.63) NPC1RAB9AGRM5PLAUF2
SCHEMBL10114593 0.75 MAPT (0.69) MAPTNPC1RAB9AHPGDSMN1; SMN2
SCHEMBL1270190 0.75 NPC1 (1.00) MAPTNPC1RAB9AHPGDSMN1; SMN2
SCHEMBL23742110 0.75 MAPT (0.78) MAPTNPC1RAB9AHPGDSMN1; SMN2
SCHEMBL15426988 0.74 GCK (0.69) MAPTNPC1RAB9AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 MAPT 3752/4885NPC1 2478/4885RAB9A 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.